Healthy
Conditions
Brief summary
The aim of the trial is to determine if the synbiotic (prebiotic and probiotic), provided twice daily (capsule) is safe and tolerable in healthy adults.
Interventions
OTHERMedical Food: SBD111
One capsule administered twice daily with morning and evening meals for 28 days
OTHERPlacebo
One capsule administered twice daily with morning and evening meals for 28 days
Sponsors
Hebrew SeniorLife
Solarea Bio, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Written informed consent 2. Stated availability throughout entire study period and willingness to fulfill all details of the protocol 3. Age 18-70 4. Be in general good health as determined by a screening evaluation within 30 days of the first dose of SBD111 or placebo 5. Willing to comply with protocol and report on compliance and side effects during study period 6. Body Mass Index between 18.5 and 35 kg/m2 7. Normal cardiovascular parameters, systolic blood pressure ≤ 155 mm Hg, diastolic blood pressure ≤ 95 mm Hg)
Exclusion criteria
1. Are currently taking probiotic or prebiotic supplements, or have taken them in the past 30 days 2. Unwilling to avoid probiotics/prebiotics supplements for the duration of the study 3. Known or suspected allergies to probiotics 4. Received oral or parenteral antibiotics within 3 months of enrollment or prescribed antibiotics on day of enrollment. 5. Major surgery or endoscopy within last 3 months. 6. Subject is a smoker 7. Subject has a history of drug and/or alcohol abuse at the time of enrolment 8. Presence of any of the following: 9. Abnormal vital signs or clinically significant systems abnormalities based on screening questionnaire 10. Indwelling catheter or implanted hardware/prosthetic device or feeding tube 11. Febrile illness (oral temperature \>37 degrees Celsius) or one or more episodes of diarrhea within 72 hours of baseline visit (first dose of study drug) 12. Active bowel leak, acute abdomen, colitis, or active GI disease or history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, or inflammatory bowel disease 13. History of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease 14. Underlying structural heart disease or previous history of endocarditis or valve replacement 15. Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy, neutrophil count \<500/mm\^3, or an anticipated drop in the neutrophil count to \<500/mm3 16. History of cancer excluding non-melanoma skin cancers or cancer more than 10 years ago 17. History of collagen vascular disease 18. Active TB 19. Women only - pregnant, planning on becoming pregnant within the next 2 months, breastfeeding, positive urine pregnancy test during screening or within 24 hours of first dose of study drug. 20. Screening laboratory tests greater than upper normal limit (ULN) or less than lower normal limit (LLN): 1. WBCs \< LLN or \> ULN 2. Neutrophils \< 1500/µl (1.5 x109/L) 3. Platelets \< 100 x 10³/µl (100 x 109/L) 4. Haemoglobin \< 9.0 g/dl (90 g/L) f. GFR of \> 40 mL/minute g. AST \> 3 x upper limit of normal h. ALT \> 3 x upper limit of normal i. Total Bilirubin \> 1.5 x upper limit of normal 21. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety as assessed by incidence of adverse advents | day-0 to day-28 | Occurrence of adverse events defined as a Grade II-IV toxicity (FDA's Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Subjects Enrolled in Preventative Vaccine Clinical Trials, September 2007), that are possibly or probably related to administration of SBD111 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal Tolerability as assessed by Gastrointestinal Tolerability Questionnaire | day-0 to day-28 | Occurrence of gastrointestinal intolerability symptoms defined as a Grade II-IV toxicity |
Other
| Measure | Time frame |
|---|---|
| Composition and function of the gut microbiome and presence of SBD111 in stool specimens by shotgun metagenomic sequencing | Day-0 to Day-28 and Day-56 (washout) |
Countries
United States
Outcome results
None listed